Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

25.27 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019201820172016
Revenue 270.259220.1838.54400000
Cost of Revenue 91.0446.9669.13.8053.2790.2860.0280.022
Gross Profit 179.219173.21429.444-3.805-3.279-0.286-0.028-0.022
Gross Profit Ratio 0.6630.7870.76400000
Reseach & Development Expenses 74.98865.4999.297112.042135.00186.59756.35717.439
General & Administrative Expenses 000034.96221.5639.0436.563
Selling & Marketing Expenses 00000000
SG&A 129.42797.95185.94845.32134.96221.5639.0436.563
Other Expenses 8.5441.2530.83500000
Operating Expenses 204.415163.441186.08157.363169.963108.1665.424.002
Operating Income -25.1967.371-156.636-157.363-169.963-108.16-65.4-24.002
Operating Income Ratio -0.0930.033-4.06400000
Total Other Income Expenses Net 8.5443.6550.0971.1346.0494.7190.5290.065
Income Before Tax -16.65211.026-156.539-156.229-163.914-103.441-64.871-23.937
Income Before Tax Ratio -0.0620.05-4.06100000
Income Tax Expense -30.736-172.3371.3855.152-2.047-0.2140.0020.036
Net Income 14.084183.363-157.924-161.381-161.867-103.227-64.873-23.973
Net Income Ratio 0.0520.833-4.09700000
EPS 0.22.64-2.3-2.61-2.99-3.49-2-0.74
EPS Diluted 0.22.6-2.3-2.61-2.99-3.49-2-0.74
EBITDA -23.0879.773-156.636-157.363-169.963-108.16-65.372-23.98
EBITDA Ratio -0.0850.044-4.06400000